Kenichiro Sato et al. performed a disproportionality analysis using the Japanese Adverse Drug Event Report database and advocated that SGLT2 inhibitors are associated with an increased risk of ischemic stroke, including thrombosis, lacunar infarction and embolism, but there was no significantly higher risk for hemorrhagic stroke10. Here, SLC5A2 is linked to ischemic stroke.